Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers

BRAF mutant metastatic colorectal cancer has long been considered a tumor with a poor prognosis and a poor response to chemotherapy. Despite the efficacy of targeted therapy with multi-targeted blockade of the mitogen-activated protein kinase (MAPK) signaling pathway has brought a glimmer of hope to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jie, Sun, Zijian, Li, Sheng, Yang, Liu, Cao, Yuepeng, Bao, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258190/
https://www.ncbi.nlm.nih.gov/pubmed/37302081
http://dx.doi.org/10.1007/s12672-023-00718-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258190/
https://www.ncbi.nlm.nih.gov/pubmed/37302081
http://dx.doi.org/10.1007/s12672-023-00718-y

Ejemplares similares